Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPAROXETINE MESYLATE (paroxetine) by Engine Biosciences is (ssri) for the treatment of moderate to severe vms associated with menopause. Approved for any psychiatric condition, moderate to severe vasomotor symptoms associated with menopause (vms) () limitations of use : paroxetine capsules are not indicated for the treatment of any psychiatric condition (), anxiety. First approved in 2017.
Drug data last refreshed 19h ago
(SSRI) for the treatment of moderate to severe VMS associated with menopause. It is identified chemically as (-)- trans -4R- (4'-fluorophenyl) - 3S - [(3', 4'-methylenedioxyphenoxy) methyl] piperidine mesylate and has the empirical formula of C 19 H 20 FNO 3 •CH 3 SO 3 H. The molecular weight is…
Worked on PAROXETINE MESYLATE at Engine Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Concentration-QT Study of Paroxetine in Healthy Adults
Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo